End-of-day quote
Bucharest S.E.
18:00:00 2024-05-01 EDT
|
5-day change
|
1st Jan Change
|
3.26
RON
|
0.00%
|
|
-3.55%
|
+11.64%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
1,543
|
2,230
|
2,021
|
1,701
|
1,352
|
2,035
|
Enterprise Value (EV)
1 |
1,138
|
1,856
|
1,620
|
1,647
|
1,360
|
2,029
|
P/E ratio
|
5.87
x
|
39.1
x
|
30.8
x
|
16.1
x
|
13.6
x
|
10.6
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
3.34
x
|
3.99
x
|
3.62
x
|
2.49
x
|
1.78
x
|
2.13
x
|
EV / Revenue
|
2.47
x
|
3.32
x
|
2.9
x
|
2.41
x
|
1.79
x
|
2.13
x
|
EV / EBITDA
|
3.53
x
|
29.4
x
|
18.7
x
|
12.6
x
|
12.2
x
|
9.73
x
|
EV / FCF
|
5.1
x
|
-25.5
x
|
1,151
x
|
-4.51
x
|
-15
x
|
-43.6
x
|
FCF Yield
|
19.6%
|
-3.92%
|
0.09%
|
-22.2%
|
-6.68%
|
-2.3%
|
Price to Book
|
2.45
x
|
3.18
x
|
2.57
x
|
1.91
x
|
1.35
x
|
1.71
x
|
Nbr of stocks (in thousands)
|
416,961
|
697,017
|
697,017
|
697,017
|
697,017
|
697,017
|
Reference price
2 |
3.700
|
3.200
|
2.900
|
2.440
|
1.940
|
2.920
|
Announcement Date
|
19-04-01
|
20-03-27
|
21-04-29
|
22-05-03
|
23-03-28
|
24-03-27
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
461.4
|
559
|
558
|
683.9
|
759.6
|
953.6
|
EBITDA
1 |
322.4
|
63.2
|
86.45
|
130.7
|
111.3
|
208.5
|
EBIT
1 |
310.3
|
46.68
|
67.52
|
107.3
|
85.71
|
185.4
|
Operating Margin
|
67.25%
|
8.35%
|
12.1%
|
15.69%
|
11.28%
|
19.44%
|
Earnings before Tax (EBT)
1 |
315.4
|
54.09
|
80.55
|
119.2
|
115
|
221.8
|
Net income
1 |
262.6
|
43.75
|
65.64
|
105.7
|
99.47
|
192.6
|
Net margin
|
56.92%
|
7.83%
|
11.76%
|
15.46%
|
13.09%
|
20.2%
|
EPS
2 |
0.6298
|
0.0819
|
0.0942
|
0.1517
|
0.1427
|
0.2763
|
Free Cash Flow
1 |
223.2
|
-72.75
|
1.407
|
-365.2
|
-90.89
|
-46.57
|
FCF margin
|
48.37%
|
-13.01%
|
0.25%
|
-53.41%
|
-11.96%
|
-4.88%
|
FCF Conversion (EBITDA)
|
69.22%
|
-
|
1.63%
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
84.98%
|
-
|
2.14%
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
19-04-01
|
20-03-27
|
21-04-29
|
22-05-03
|
23-03-28
|
24-03-27
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
7.62
|
-
|
Net Cash position
1 |
405
|
375
|
401
|
53.2
|
-
|
6.15
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
0.0685
x
|
-
|
Free Cash Flow
1 |
223
|
-72.8
|
1.41
|
-365
|
-90.9
|
-46.6
|
ROE (net income / shareholders' equity)
|
52.6%
|
6.57%
|
8.83%
|
12.6%
|
10.5%
|
17.6%
|
ROA (Net income/ Total Assets)
|
27.8%
|
3.05%
|
4.11%
|
6.44%
|
4.75%
|
8.57%
|
Assets
1 |
944.8
|
1,437
|
1,595
|
1,642
|
2,093
|
2,248
|
Book Value Per Share
2 |
1.510
|
1.010
|
1.130
|
1.280
|
1.430
|
1.710
|
Cash Flow per Share
2 |
0.9700
|
0.5600
|
0.5800
|
0.0900
|
0.0200
|
0.0400
|
Capex
1 |
22.2
|
35.6
|
24.5
|
22.9
|
27.4
|
28
|
Capex / Sales
|
4.82%
|
6.36%
|
4.4%
|
3.35%
|
3.61%
|
2.93%
|
Announcement Date
|
19-04-01
|
20-03-27
|
21-04-29
|
22-05-03
|
23-03-28
|
24-03-27
|
|
1st Jan change
|
Capi.
|
---|
| +11.64% | 492M | | +19.98% | 43.48B | | +20.67% | 22.65B | | +14.56% | 14.73B | | +14.32% | 13.79B | | +44.72% | 12.04B | | -8.37% | 7.08B | | -0.05% | 6.79B | | -8.87% | 5.73B | | +11.90% | 5.47B |
Generic Pharmaceuticals
|